|
|
|
|
| LEADER |
00000cam a2200000Mi 4500 |
| 001 |
EBOOKCENTRAL_on1028945030 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
180317s2018 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d DKU
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCO
|d REDDC
|d OCLCF
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCL
|
| 020 |
|
|
|a 9783527687190
|
| 020 |
|
|
|a 352768719X
|
| 029 |
1 |
|
|a GBVCP
|b 1018224971
|
| 035 |
|
|
|a (OCoLC)1028945030
|
| 050 |
|
4 |
|a RM301.25
|b .T736 2018
|
| 082 |
0 |
4 |
|a 615.19
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Meyers, Robert A.
|
| 245 |
1 |
0 |
|a Translational Medicine :
|b Molecular Pharmacology and Drug Discovery.
|
| 260 |
|
|
|a Somerset :
|b John Wiley & Sons, Incorporated,
|c 2018.
|
| 300 |
|
|
|a 1 online resource (1058 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Current Topics from the Encyclopedia of Molecular Cell Biology and Molecular Medicine Ser.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Cover; Title Page; Copyright; Contents; Preface; Volume 1; Part I Biopharmaceuticals; Chapter 1 Analogs and Antagonists of Male Sex Hormones; 1 Introduction; 2 Historical; 3 Endogenous Male Sex Hormones; 3.1 Occurrence and Physiological Roles; 3.2 Biosynthesis; 3.3 Absorption and Distribution; 3.4 Metabolism; 3.4.1 Reductive Metabolism; 3.4.2 Oxidative Metabolism; 3.5 Mechanism of Action; 4 Synthetic Androgens; 4.1 Current Drugs on the Market; 4.2 Therapeutic Uses and Bioassays; 4.3 Structure-Activity Relationships for Steroidal Androgens; 4.3.1 Early Modifications.
|
| 505 |
8 |
|
|a 4.3.2 Methylated Derivatives4.3.3 Ester Derivatives; 4.3.4 Halo Derivatives; 4.3.5 Other Androgen Derivatives; 4.3.6 Summary of Structure-Activity Relationships of Steroidal Androgens; 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs); 4.5 Absorption, Distribution, and Metabolism; 4.6 Toxicities; 5 Anabolic Agents; 5.1 Current Drugs on the Market; 5.2 Therapeutic Uses and Bioassays; 5.3 Structure-Activity Relationships for Anabolic Agents; 5.3.1 19-Nor Derivatives; 5.3.2 Dehydro Derivatives; 5.3.3 Alkylated Analogs; 5.3.4 Hydroxy and Mercapto Derivatives.
|
| 505 |
8 |
|
|a 5.3.5 Oxa, Thia, and Aza Derivatives5.3.6 Deoxy and Heterocyclic-Fused Analogs; 5.3.7 Esters and Ethers; 5.3.8 Summary of Structure-Activity Relationships; 5.4 Absorption, Distribution, and Metabolism; 5.5 Toxicities; 5.6 Abuse of Anabolic Agents; 6 Androgen Antagonists; 6.1 Current Drugs on the Market; 6.2 Antiandrogens; 6.2.1 Therapeutic Uses; 6.2.2 Structure-Activity Relationships for Antiandrogens; 6.2.3 Absorption, Distribution, and Metabolism; 6.2.4 Toxicities; 6.3 Enzyme Inhibitors; 6.3.1 5a-Reductase Inhibitors; 6.3.2 17,20-Lyase Inhibitors; 6.3.3 C19 Steroids as Aromatase Inhibitors.
|
| 505 |
8 |
|
|a 7 SummaryAcknowledgments; Chapter 2 Annexins; 1 Diversity and Functions; 2 Structure and Mechanism of Action; 3 Regulation; 4 Applications; References; Chapter 3 Genetic Engineering of Antibody Molecules; 1 Antibody Structure and Engineering; 1.1 The Basic Structure of Antibodies; 1.2 Classes and Subclasses of Antibodies; 2 Technological Milestones in Antibody Engineering; 2.1 Murine Monoclonal Antibodies; 2.2 Chimeric Antibodies; 2.3 Humanized Antibodies; 2.4 Fully Human Antibodies; 3 Expression Systems; 3.1 Prokaryotic Expression Systems; 3.2 Yeast Expression Systems.
|
| 505 |
8 |
|
|a 3.3 Insect Cell Expression Systems3.4 Mammalian Cell Expression Systems; 3.5 Antibody Expression in Transgenic Plants; 3.6 Transgenic Mammals; 4 Variable Region Engineering; 4.1 Improving the Affinity of Recombinant Antibodies; 4.2 Reduction of Immunogenicity; 5 Constant Region Engineering; 5.1 Fc Engineering of IgGs for ADCC and ADCP Functions; 5.2 Fc Engineering of IgGs for CDC Function; 5.3 Antibody Engineering for Altered Half-Life; 5.4 Antibodies of the IgE Class; 6 Structurally Modified Antibodies; 6.1 Antibody Fragments: Fabs and scFvs Monovalent, Bivalent, and Multivalent.
|
| 500 |
|
|
|a 6.2 Bispecific Antibodies.
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Molecular pharmacology.
|
| 650 |
|
2 |
|a Translational Research, Biomedical.
|
| 650 |
|
2 |
|a Molecular Mechanisms of Pharmacological Action
|
| 650 |
|
2 |
|a Drug Discovery
|
| 650 |
|
6 |
|a Médicaments
|x Développement.
|
| 650 |
|
6 |
|a Pharmacologie moléculaire.
|
| 650 |
|
7 |
|a Drug development
|2 fast
|
| 650 |
|
7 |
|a Molecular pharmacology
|2 fast
|
| 758 |
|
|
|i has work:
|a Volume 1 Translational medicine (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCG77r33qXF3VXv3rKdWgPP
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Meyers, Robert A.
|t Translational Medicine : Molecular Pharmacology and Drug Discovery.
|d Somerset : John Wiley & Sons, Incorporated, ©2018
|z 9783527336593
|
| 830 |
|
0 |
|a Current Topics from the Encyclopedia of Molecular Cell Biology and Molecular Medicine Ser.
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=5317903
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL5317903
|
| 994 |
|
|
|a 92
|b IZTAP
|
